Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
From aging biology to cardiac biotechnology: emerging platforms for modeling cardiac aging
Kritika Chaddha, Mabel Bartlett, Tzahi Cohen-Karni, Aditi Gurkar
Kritika Chaddha, Mabel Bartlett, Tzahi Cohen-Karni, Aditi Gurkar
View: Text | PDF
Review Series

From aging biology to cardiac biotechnology: emerging platforms for modeling cardiac aging

  • Text
  • PDF
Abstract

Aging is a major contributor to cardiovascular disease and mortality in older adults. Yet most preclinical and experimental cardiac studies fail to account for age as a primary biological variable, leaving a critical gap in our understanding of how aging contributes to disease progression. Bridging this gap requires integrating aging biology, cardiac pathophysiology, and cutting-edge biotechnology to uncover the mechanisms underlying age-related cardiac dysfunction. We offer a new approach methodologies (NAMs) perspective on how emerging bioengineering strategies may reshape the study of cardiac aging by enabling multidimensional monitoring of cardiac function, aging trajectories, and therapeutic responses. To capture this complexity, we propose the A×G×E×D framework, where A stands for age, G for genetics, E for environment, and D for drug exposure, as a multidimensional lens for understanding how these factors converge to determine cardiac vulnerability during aging. We highlight the integration of long-term cardiac microtissues with advancements in biotechnology to model age. This Perspective opens new frontiers for understanding how A×G×E×D interactions manifest at the molecular, cellular, and electrophysiological levels and for designing responsive, personalized interventions that align with each individual’s evolving physiology. By developing robust bioengineered platforms that recapitulate human cardiac aging, we can advance toward precision geromedicine for cardiovascular health.

Authors

Kritika Chaddha, Mabel Bartlett, Tzahi Cohen-Karni, Aditi Gurkar

×

Figure 2

Advancing human cardiac modeling platforms from 2D cultures to complex 3D systems.

Options: View larger image (or click on image) Download as PowerPoint
Advancing human cardiac modeling platforms from 2D cultures to complex 3...
Schematic overview of model platform progression. (A) 2D monoculture and coculture systems. (B) 3D microtissues enable multicellular organization. (C) Self-assembled organoids/organ-on-chip platforms. (D) Microphysiological systems (MPS) enhance physiological relevance with perfusion and multiorgan integration. (E) Panomic benchmarking (genomics, transcriptomics, proteomics, metabolomics) ensures model fidelity to human heart capturing A×G×E×D.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts